对克拉通在人类中的治疗潜力和安全性的临床(前)研究的系统回顾

IF 1.8 4区 医学 Q3 CLINICAL NEUROLOGY
Elisabeth Prevete, Kim Paula Colette Kuypers, Eef Lien Theunissen, Ornella Corazza, Giuseppe Bersani, Johannes Gerardus Ramaekers
{"title":"对克拉通在人类中的治疗潜力和安全性的临床(前)研究的系统回顾","authors":"Elisabeth Prevete,&nbsp;Kim Paula Colette Kuypers,&nbsp;Eef Lien Theunissen,&nbsp;Ornella Corazza,&nbsp;Giuseppe Bersani,&nbsp;Johannes Gerardus Ramaekers","doi":"10.1002/hup.2805","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Kratom <i>(Mitragyna speciosa)</i> is a tropical plant traditionally used as an ethnomedicinal remedy for several conditions in South East Asia. Despite the increased interest in its therapeutical benefits in Western countries, little scientific evidence is available to support such claims, and existing data remain limited to kratom's chronic consumption.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>Our study aims to investigate (pre)clinical evidence on the efficacy of kratom as a therapeutic aid and its safety profile in humans.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic literature search using PubMed and the Medline database was conducted between April and November 2020.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Both preclinical (<i>N</i> = 57) and clinical (<i>N</i> = 18) studies emerged from our search. Preclinical data indicated a therapeutic value in terms of acute/chronic pain (<i>N</i> = 23), morphine/ethanol withdrawal, and dependence (<i>N</i> = 14), among other medical conditions (<i>N</i> = 26). Clinical data included interventional studies (<i>N</i> = 2) reporting reduced pain sensitivity, and observational studies (<i>N</i> = 9) describing the association between kratom's chronic (daily/frequent) use and safety issues, in terms of health consequences (e.g., learning impairment, high cholesterol level, dependence/withdrawal).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Although the initial (pre)clinical evidence on kratom's therapeutic potential and its safety profile in humans is encouraging, further validation in large, controlled clinical trials is required.</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"37 1","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/hup.2805","citationCount":"25","resultStr":"{\"title\":\"A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans\",\"authors\":\"Elisabeth Prevete,&nbsp;Kim Paula Colette Kuypers,&nbsp;Eef Lien Theunissen,&nbsp;Ornella Corazza,&nbsp;Giuseppe Bersani,&nbsp;Johannes Gerardus Ramaekers\",\"doi\":\"10.1002/hup.2805\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Kratom <i>(Mitragyna speciosa)</i> is a tropical plant traditionally used as an ethnomedicinal remedy for several conditions in South East Asia. Despite the increased interest in its therapeutical benefits in Western countries, little scientific evidence is available to support such claims, and existing data remain limited to kratom's chronic consumption.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>Our study aims to investigate (pre)clinical evidence on the efficacy of kratom as a therapeutic aid and its safety profile in humans.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A systematic literature search using PubMed and the Medline database was conducted between April and November 2020.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Both preclinical (<i>N</i> = 57) and clinical (<i>N</i> = 18) studies emerged from our search. Preclinical data indicated a therapeutic value in terms of acute/chronic pain (<i>N</i> = 23), morphine/ethanol withdrawal, and dependence (<i>N</i> = 14), among other medical conditions (<i>N</i> = 26). Clinical data included interventional studies (<i>N</i> = 2) reporting reduced pain sensitivity, and observational studies (<i>N</i> = 9) describing the association between kratom's chronic (daily/frequent) use and safety issues, in terms of health consequences (e.g., learning impairment, high cholesterol level, dependence/withdrawal).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Although the initial (pre)clinical evidence on kratom's therapeutic potential and its safety profile in humans is encouraging, further validation in large, controlled clinical trials is required.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13030,\"journal\":{\"name\":\"Human Psychopharmacology: Clinical and Experimental\",\"volume\":\"37 1\",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2021-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/hup.2805\",\"citationCount\":\"25\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Psychopharmacology: Clinical and Experimental\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hup.2805\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2805","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 25

摘要

Kratom (Mitragyna speciosa)是一种热带植物,传统上用作东南亚几种疾病的民族药物。尽管西方国家对其治疗益处的兴趣越来越大,但几乎没有科学证据支持这种说法,现有的数据仍然仅限于kratom的长期消费。目的研究克拉通作为一种治疗辅助药物的疗效及其在人体中的安全性。方法于2020年4月至11月,利用PubMed和Medline数据库进行系统文献检索。结果临床前研究(N = 57)和临床研究(N = 18)均出现在我们的搜索中。临床前数据显示,在急性/慢性疼痛(N = 23)、吗啡/乙醇戒断和依赖性(N = 14)以及其他医疗条件(N = 26)方面,该药具有治疗价值。临床数据包括报告疼痛敏感性降低的介入性研究(N = 2)和描述慢性(每日/频繁)使用kratom与健康后果(如学习障碍、高胆固醇水平、依赖/戒断)安全问题之间关联的观察性研究(N = 9)。虽然关于kratom的治疗潜力及其在人类中的安全性的初步(预)临床证据令人鼓舞,但需要在大型对照临床试验中进一步验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans

A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans

A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans

Introduction

Kratom (Mitragyna speciosa) is a tropical plant traditionally used as an ethnomedicinal remedy for several conditions in South East Asia. Despite the increased interest in its therapeutical benefits in Western countries, little scientific evidence is available to support such claims, and existing data remain limited to kratom's chronic consumption.

Objective

Our study aims to investigate (pre)clinical evidence on the efficacy of kratom as a therapeutic aid and its safety profile in humans.

Methods

A systematic literature search using PubMed and the Medline database was conducted between April and November 2020.

Results

Both preclinical (N = 57) and clinical (N = 18) studies emerged from our search. Preclinical data indicated a therapeutic value in terms of acute/chronic pain (N = 23), morphine/ethanol withdrawal, and dependence (N = 14), among other medical conditions (N = 26). Clinical data included interventional studies (N = 2) reporting reduced pain sensitivity, and observational studies (N = 9) describing the association between kratom's chronic (daily/frequent) use and safety issues, in terms of health consequences (e.g., learning impairment, high cholesterol level, dependence/withdrawal).

Conclusions

Although the initial (pre)clinical evidence on kratom's therapeutic potential and its safety profile in humans is encouraging, further validation in large, controlled clinical trials is required.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
34
审稿时长
6-12 weeks
期刊介绍: Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信